Skip to search formSkip to main contentSkip to account menu

GM2-KLH vaccine

Known as: GM2-KLH, GM2-KLH ganglioside, KLH-conjugated GM2 Ganglioside Vaccine 
A cancer vaccine consisting of GM2 ganglioside, a melanoma-specific antigen, conjugated with the immunostimulant keyhole limpet hemocyanin… 
National Institutes of Health

Related topics

Related topics

1 relation
GM2-KLH vaccine/QS21

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Vaccination Shows No Benefit for Primary Melanomas
The use of GM2-KLH/QS-21 vaccination in stage II melanoma patients did not improve outcomes, according to the results of the… 
2010
2010
Abstract 2418: Low dose antibody against GM2 ganglioside results in accelerated tumor growth
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC A variety of monoclonal antibodies have… 
2000
2000
Vaccination with a Bivalent GM 2 and GD 2 Ganglioside Conjugate Vaccine : A Trial Comparing Doses of GD 2-Keyhole Limpet Hemocyanin 1
Immunization with GMK vaccine (G M2 ganglioside conjugated to keyhole limpet hemocyanin mixed with QS-21 adjuvant) induces anti… 
Review
1998
Review
1998
Adjuvant therapy of melanoma.
Patients with AJCC Stage IIB and III melanoma have a poor 5-year survival rate which has been the driving force behind attempts… 
Highly Cited
1997
Highly Cited
1997
Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies
Abstract Natural IgM antibodies against the melanoma cell-surface ganglioside GM2, and IgM antibodies induced by vaccination with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)